{"a": [["Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol", "2005"], ["Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus", "1997"], ["Report of the Expert Committee on the diagnosis and classification of diabetes mellitus", "1999"], ["Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation", "2005"], ["Initiating and maintaining physical activity for type 2 diabetes mellitus", "2004"], ["Meglitinide analogues for type 2 diabetes mellitus", "2003"], ["Thiazolidinediones", "2005"], ["Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti\u2010diabetic agents", "2002"], ["Efficacy of rosiglitazone and pioglitazone compared to other anti\u2010diabetic agents: systematic review and budget impact analysis", "2003"], ["Intranasal insulin for type 1 diabetes mellitus", "2005"], ["A meta\u2010analysis comparing the effect of thiazolidinediones on cardiovascular risk factors", "2004"], ["A coefficient of agreement for nominal scales", "1960"], ["Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus", "2005"], ["Rosiglitazone maleate/metformin hydrochloride: A new formulation therapy for type 2 diabetes", "2004"], ["Clinical effectiveness and cost\u2010effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: A systematic review and economic evaluation", "2004"], ["The effect of intensive treatment of diabetes on the development and progression of long\u2010term complications in insulin\u2010dependent diabetes mellitus", "1993"], ["Pathogenesis of NIDDM: a balanced overview", "1992"], ["Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial", "2005"], ["The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study", "2001"], ["Composite outcomes in randomized trials: greater precision but with greater uncertainty?", "2003"], ["Lifestyle interventions for preventing type 2 diabetes mellitus", "2001"], ["The peroxisome proliferator\u2010activated receptor\u2010gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial", "2007"], ["Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction", "1998"], ["Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications", "1993"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]", "2005"], ["The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment", "1997"], ["Rosiglitazone in the management of older patients with type 2 diabetes mellitus", "2002"], ["Hyperglycemia and cardiovascular disease in type 2 diabetes", "1999"], ["The case of the misleading funnel plot", "2006"], ["Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone", "2007"], ["Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction", "2002"], ["Sulfonylureas for treating type 2 diabetes mellitus", "2002"], ["Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review", "2000"], ["A prospective study of maturity\u2010onset diabetes mellitus and risk of coronary heart disease and stroke in women", "1991"], ["Second\u2010generation thiazolidinediones and hepatotoxicity", "2004"], ["Analysis and reporting of factorial trials: a systematic review", "2003"], ["Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study", "2000"], ["Hepatic injury in a patient taking rosiglitazone", "2005"], ["Progress with thiazolidinediones in the management of type 2 diabetes mellitus", "2004"], ["Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus", "2005"], ["Improving the quality of reports of meta\u2010analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta\u2010analyses", "1999"], ["Design, analysis and presentation of factorial randomised controlled trials", "2003"], ["Dietary advice for the prevention of type 2 diabetes mellitus in adults", "2005"], ["Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone", "2005"], ["Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study", "1998"], ["Guidance on rosiglitazone for Type 2 diabetes mellitus", "2000"], ["Guidance on the use of glitazones for the treatment of type 2 diabetes", "2003"], ["Review of rosiglitazone and pioglitazone for type II diabetes \u2010 appraisal (project)", "2003"], ["Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", "2007"], ["Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non\u2010insulin\u2010dependent mellitus: a randomized prospective 6\u2010year study", "1995"], ["Rosiglitazone and cardiovascular risk", "2007"], ["'Human' insulin versus animal insulin in people with diabetes mellitus", "2005"], ["Pioglitazone for type 2 diabetes mellitus", "2006"], ["Dipeptidyl peptidase\u20104 (DPP\u20104) inhibitors for type 2 diabetes mellitus", "2007"], ["Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus", "2005"], ["Inhaled insulin in diabetes mellitus", "2003"], ["Performance of an NIDDM screening questionnaire based on symptoms and risk factors", "1997"], ["Metformin monotherapy for type 2 diabetes mellitus", "2005"], ["Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus", "2003"], ["Thiazolidinedione use and bone loss in older diabetic adults", "2006"], ["Diabetes, TZDs, and bone: A review of the clinical evidence", "2006"], ["Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus", "2004"], ["Glucagon\u2010like peptide analogues for type 2 diabetes mellitus", "2007"], ["Diabetes, other risk factors, and 12\u2010year cardiovascular mortality for men screened in the multiple risk factor intervention trial", "1993"], ["Investigating and dealing with publication and other biases", "2001"], ["Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study", "2000"], ["Liver failure in a patient receiving rosiglitazone therapy", "2006"], ["Misleading funnel plot for detection of bias in meta\u2010analysis", "2000"], ["Exercise for type 2 diabetes mellitus", "2001"], ["Publication bias in meta\u2010analysis: its causes and consequences", "2000"], ["Effects of hypoglycemic agents on vascular complications in patients with adult\u2010onset diabetes, VIII. Evaluation of insulin therapy: final report", "1982"], ["U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease", "1995"], ["Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\u2010UKPDS 33", "1998"], ["Effect of intensive blood\u2010glucose control with metformin on complications in overweight patients with type 2 diabetes", "1998"], ["Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38", "1998"], ["Alpha\u2010glucosidase inhibitors for type 2 diabetes mellitus", "2005"], ["Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus", "2002"], ["Slow glucose removal rate and hyperinsulinemia precede the development of Type 2 diabetes in the offspring of diabetic parents", "1990"], ["Rosiglitazone/Metformin", "2005"], ["WHO Expert Committee on Diabetes Mellitus", "1980"], ["WHO Expert Committee on Diabetes Mellitus", "1985"], ["Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3\u2010kinase pathway", "2001"], ["Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men", "2007"]], "ex": [["Rosiglitazone/metformin fixed\u2010dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24\u2010week, multicenter, randomized, double\u2010blind, parallel\u2010group study", "2005"], ["Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half\u2010maximal doses of a sulphonylurea", "2004"], ["Rosiglitazone in Type 2 diabetes mellitus: An evaluation in British Indo\u2010Asian patients", "2003"], ["Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double\u2010blind trial", "2004"], ["Insulin sensitizer combination therapy for type 2 diabetes", "2001"], ["Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control", "2003"], ["Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes", "2002"], ["Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes", "2004"], ["Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus", "2004"], ["Results of a randomized, double\u2010blind, placebo\u2010controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy", "2004"], ["Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients", "2005"], ["A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin\u2010treated type 2 diabetes", "2001"], ["Rosiglitazone amplifies the benefits of lifestyle intervention measures in long\u2010standing type 2 diabetes mellitus", "2002"], ["Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) Study", "2005"], ["The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes", "2005"], ["Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy", "2005"], ["An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes", "2002"], ["Peroxisome proliferator\u2010activated receptor\u2010gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty", "2005"], ["Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study", "2005"], ["Addition of low\u2010dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients", "2000"], ["Rosiglitazone reduces insulin requirements and c\u2010reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis", "2005"], ["Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C", "2003"]], "in": [["Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride", "2005"], ["Metformin\u2010pioglitazone and metformin\u2010rosiglitazone effects on non\u2010conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome", "2006"], ["Long\u2010term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12\u2010month, double\u2010blind, randomized trial", "2005"], ["Metformin\u2010glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy", "2006"], ["A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia", "2005"], ["A one\u2010year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes", "2007"], ["Enhancement of insulin\u2010stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone", "2004"], ["The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus", "2005"], ["Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", "2007"], ["Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1\u2010year randomized clinical trial", "2006"], ["Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus", "2002"], ["Effect of rosiglitazone versus insulin on the pancreatic beta\u2010cell function of subjects with type 2 diabetes", "2004"], ["Once\u2010 and twice\u2010daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes", "2001"], ["Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone", "2004"], ["Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin\u2010naive patients", "2006"], ["A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes", "2007"], ["Rosiglitazone reduces urinary albumin excretion in type II diabetes", "2003"], ["Synthetic peroxisome proliferator\u2010activated receptor\u2010gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients", "2002"]]}